WO1998057910A2 - Cyclooxygenase-i selective inhibitors and the use thereof as analgesic, antiinflammatory and antiarthritic agents - Google Patents
Cyclooxygenase-i selective inhibitors and the use thereof as analgesic, antiinflammatory and antiarthritic agents Download PDFInfo
- Publication number
- WO1998057910A2 WO1998057910A2 PCT/EP1998/003636 EP9803636W WO9857910A2 WO 1998057910 A2 WO1998057910 A2 WO 1998057910A2 EP 9803636 W EP9803636 W EP 9803636W WO 9857910 A2 WO9857910 A2 WO 9857910A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- alkyl
- hydrogen
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
Definitions
- the present invention relates to compounds of general formula I,
- the present invention also relates to a process for the preparation of the compounds as well as to the therapeutic use thereof.
- AA is metabolized in mammals mainly by two different pathways or enzyme systems.
- lipoxygenase Through lipoxygenase it produces leukotrienes, the most important being LTB 4 , and the peptide- leukotrienes LTC 4 , LTD 4 and LTE 4 . All of them are also involved in inflammatory reactions (Bailey and Casey, Ann. Rep. Med.Chem.. H, 203 (1982)).
- prostaglandins and thromboxanes are produced, the most significant being PGE 2 and TxA 2 .
- Prostaglandins are directly involved in gastrointestinal mucosa function, renal function and the like and also as mediators of both acute and chronic inflammation.
- NSAIDs non steroidal antiinflammatory compounds
- COX-II is related with the modulation action of prostaglandins on the gastric mucosa and the renal functions
- COX-II seems to be related with the function of these compounds as mediators in the inflammatory response (W. Xie, et al.. Drug Dev , Res , , 21 , 249- 265 ( 1992 ) ) .
- NSAIDs in the treatment of inflammation and as analgesics and antiarthritics , etc. is widespread and well documented (C.S. Boynton, et al ... J. Clin.
- nitrous oxide (NO) donor compounds of COX-II selective inhibitors and of compounds with a structure having both characteristics .
- cyclooxygenase-II selective inhibitors As for the use of cyclooxygenase-II selective inhibitors, the advantages deriving from their lower lesive effects on the gastrointestinal tract and on kidney have already been described in tests on healthy animals. On the contrary, the use of cyclooxygenase-II inhibitors in animal models with pre-existent gastrointestinal lesions provides no such beneficial effects. Thus, the use of these compounds in animal models with gastric ulcer delays their natural healing process, as it happens with traditional NSAIDs (A. Schmassmann et al... Gastroenterolo ⁇ v. HQ_ (4) Suppl. A252 (1996) and B.M. Peskar et al... Prosta ⁇ l . Leukotr. and Ess. Fattv Acids. 15. (1) 45 (1996)).
- COX-II selective inhibitors that have clearly shown to be beneficial in the treatment of healthy animals (A. Ford-Hutchinson et al... , W0- 94/13635 (1994)), were found to increase, in rats with induced ulcerative colitis, the incidence and the severity of the lesions, as well as the mortality rate therefrom (B.K. Reuter et al... J. Clin. Invest.. 98 (9) 2076-2085 (1996)).
- the compounds of the present invention are cyclooxygenase-I inhibitors, while having a poor activity on cyclooxygenase-II. How it is to be expected from their action at the cellular level, these compounds are analgesics and antinflammatories in in vivo animal models.
- the cyclooxygenase- I selective compounds lack the characteristic gastrointestinal side-effects of non-selective NSAIDs as well as those of the cyclooxygenase-II inhibitors.
- the compounds I neither worsen ulcers or erosions, nor increase their incidence or delay their healing.
- the present invention relates to compounds of general formula I,
- A is a -COOR -SO3R 4 ⁇ S0 2 NHCOR- -S0 2 NHCOOR*, -S0 2 NHCONHR 4 , -CONHOR 4 , -CON(OH)R 4 , -N(OH)CONH 2 , -N(OH)COR 4 , -CONHS0 2 R 5 group or a 5-tetrazolyl group;
- B is a single bond or a diradical which represents a (C ⁇ -C 4 )-alkyl or alkenyl group, a -CO- group, an oxygen atom, a sulfur atom, a NR 4 group, a -C0N(R 4 )- group or a -N(R )C0- group;
- D is hydrogen, a (C ⁇ -Cg )-alkyl , alkenyl or alkynyl group, a ( C -C7 )-cycloalkyl or cycloalkenyl group, all these groups optionally having one or more hydrogen atoms substituted by halogen atoms, hydroxy groups, (C 1 -C 4 )-alkoxide groups or (C ⁇ -C 4 )- alkyl groups;
- R 1 and R 2 are independently hydrogen, (C ⁇ -Cg )-alkyl or ( C3 ⁇ Cg )-cycloalkyl or, taken together, they form a (C 3 -C )-cycloalkyl;
- R 3 is hydrogen, fluorine, chlorine, bromine, (C * -
- R 4 is hydrogen, a ( C- « -C 4 )-alkyl or a phenylakyl group of less than 10 carbon atoms;
- R ⁇ is the same as R 4 except hydrogen, provided that the compound of formula I is other than: 3-chloro-4- ( 2-propenyloxy )benzeneacetic acid; ⁇ -methyl-4- [ ( 2-methyl-2-propenyl ) amino]benzeneacetic acid; ⁇ -methyl-4- ( 2-methylpropyl )benzeneacetic acid; 4- ( 2-methylpropyl )benzeneacetic acid; and N-hydroxy- ⁇ -methyl-4-( 2-methylpropyl )benzenea.cetami- de.
- the present invention also relates to the pharmaceutically acceptable salts and solvates of the compounds of formula I, and in particular the salts represented by the formula la,
- M + is an alkali metal cation (e.g. Na + , K + ) , or the half amount of an alkaline-earth metal cation (e.g.
- the compounds of formula I can have one or more asymmetric carbons in their structure.
- the present invention comprises all the possible stereoisomers as well as the mixtures thereof.
- the compounds of general formula I can be obtained through any one of the following processes: a) A compound of formula Ila,
- R 2 CH , wherein D, B, R 3 and R 4 represent the groups defined above, can be obtained by reaction of a compound of formula V,
- VI corresponds to lib where R 4 is a methyl group or is converted to lib where R 4 is hydrogen by saponification of the methyl ester by treatment with a suitable base, such as lithium or sodium hydroxide in aqueous solution in a suitable organic solvent, such as methanol, ethanol or tetrahydrofuran, at a temperature ranging between 20°C and the solvent reflux for a time between 1 and 48 hours .
- a suitable base such as lithium or sodium hydroxide in aqueous solution in a suitable organic solvent, such as methanol, ethanol or tetrahydrofuran
- lid i.e. of general formula I where R ⁇ and R 3 are hydrogen
- R 2 is a methyl group
- A is COOR 4 and B is a G group bound to the phenyl group at the para position to the propionate substituent, wherein G represents an oxygen or sulfur atom, a NR 4 group and D and R 3 represent the groups described above, can be prepared starting from a compound of formula VIII,
- R 3 , R ⁇ and G represent the groups defined above, commercial or easily available following simple chemical processes, by alkylation reaction of the heteroatom contained in G with a compound IX,
- X is a chlorine or bromine atom or an alkyl or aryl sulfonate group.
- the reaction between VIII and IX when G is an amino group is carried out by treatment of a compound VIII with an excess of IX where X is bromine at a temperature from 60 to 170°C for a time between 4 and 24 h.
- G sulfur
- the reaction is carried out subjecting compound VIII to the action of a base such as a metal hydroxide or carbonate and subsequently reacting it with a compound IX in a suitable organic solvent such as N,N-dimethylformamide , ethanol or methanol at a temperature ranging between 0° and 100°C and for a time between 2 and 24 hours.
- the reaction can be carried out in the presence of a base such as a metal hydride, in a suitable solvent, such as N,N- dimethylformamide , tetrahydrofuran or benzene, at a temperature ranging between 25° and 120 °C and for a time from 4 to 24 hours.
- a base such as a metal hydride
- a suitable solvent such as N,N- dimethylformamide , tetrahydrofuran or benzene
- a compound lid can be obtained by reaction between a compound VIII and a compound IX in the general conditions of the Mitsunobu reaction; i.e., in the presence of diethyl azodicarboxylate and triphenylphosphine in a suitable solvent such as tetrahydrofuran at room temperature and for a time between 24 and 72 hours, e)
- a compound of general formula I where A is a CONHOR 4 , CON(R 4 )OH or CONHS0 2 R 5 group can be obtained starting from a compound Ila where R 4 is hydrogen by reaction of the acid chloride Ila, obtained, for example, by treatment with oxalyl chloride under reflux for 0.5-4 hours, with a compound R 4 ONH 2 , HONR 4 or R 5 S0 2 NH 2 , respectively, in the presence of an organic amine such as pyridine or triethylamine , in a suitable solvent such as tetrahydrofuran or N,N- di
- D, B, R 3 and X represent the groups defined above, by reaction with sodium sulphite in a suitable solvent such as ethanol, 1,4-dioxane or N,N- dimethylformamide at a temperature ranging between 25 °C and the solvent reflux and for a time between 1 and 24 h.
- a suitable solvent such as ethanol, 1,4-dioxane or N,N- dimethylformamide
- XIa corresponds to lie where R 4 is hydrogen, or it is converted to lie where R 4 is different from hydrogen by esterification of XIa in the usual conditions for the esterif ication of sulfonic acids, g) A compound of formula Ilf,
- a starting compound of general formula V. can be obtained, for example, starting from a compound XII following the process described in scheme 1 Scheme 1
- a compound XIII is obtained by reaction of a starting compound XII with methyl propionate in the presence of a base, such as a metal hydride, in a suitable solvent such as xylene, toluene or tetrahydrofuran at a temperature between 80 and 140°C for a time between 3 and 24 h (step 1).
- a compound V is obtained by hydrolysis and decarboxylation in acidic medium of a compound XIII using, for example, a mixture of acetic acid and hydrochloric acid at the reflux temperature of the mixture and for a time ranging between 4 and 24 h (step 2).
- a starting compound of formula Va i.e. of general formula V where B is a methylene group can be obtained, for example, through the process which is showed in scheme 2.
- a compound XV is obtained by protection of the carbonyl group of a compound XIV, commercial or easily available through simple chemical processes, with ethylene glycol in the presence of catalytic amounts of p-toluenesulfonic acid in a suitable solvent in which the azeotropical removal of the water is possible, such as benzene or toluene, at the solvent reflux temperature and for a time ranging between 5 and 24 h (step 3).
- a compound of formula XVIII is obtained preparing the organolithium derivative XVI by treating XV with n-butyllithium or tert-butyllithium at -78°C in an inert solvent such as ethyl ether or tetrahydrofuran for a time between 1 and 4 h (step 4), and reacting it immediately with an aldehyde XVII for a time between 4 and 24 h at a temperature between 0 and the solvent reflux ( step 5 ) .
- an inert solvent such as ethyl ether or tetrahydrofuran
- a compound of formula XIX can be obtained by direct catalytic hydrogenation of a compound XVIII with 10% palladium-on-charcoal in a suitable solvent such as dichloromethane , ethyl acetate, ethanol or mixtures thereof, optionally in the presence of a weak acid, such as acetic acid, at room pressure and temperature and for a time from 8 to 24 h (step 6).
- a suitable solvent such as dichloromethane , ethyl acetate, ethanol or mixtures thereof, optionally in the presence of a weak acid, such as acetic acid, at room pressure and temperature and for a time from 8 to 24 h (step 6).
- the hydroxy group of compound XVIII can be activated before the hydrogenolytic process by formation of an acetate, obtainable by treatment of compound XVIII with acetic anhydride in the presence of an organic base such as triethylamine in a suitable solvent such as chloroform or tetrahydrofuran at a temperature between 25°C and the solvent reflux.
- an organic base such as triethylamine
- a suitable solvent such as chloroform or tetrahydrofuran at a temperature between 25°C and the solvent reflux.
- a compound Va is obtained by treatment in acidic medium of a compound XIX, for example, with sulfuric acid or hydrochloric diluted or concentrated acid, in a solvent such as tetrahydrofuran or ethanol at a temperature between the room temperature and the solvent reflux for a time between 2 and 18 h (step 7).
- a compound of formula Vb is obtained by treatment in acidic medium of a compound XIX, for example, with sulfuric acid or hydrochloric diluted or concentrated acid, in a solvent such as tetrahydrofuran or ethanol at a temperature between the room temperature and the solvent reflux for a time between 2 and 18 h (step 7).
- a compound of formula Vb is obtained by treatment in acidic medium of a compound XIX, for example, with sulfuric acid or hydrochloric diluted or concentrated acid, in a solvent such as tetrahydrofuran or ethanol at a temperature between the room temperature and the solvent reflux for a time between 2 and 18 h (step 7
- Vb i.e. of general formula V where B is a carbonyl group and D is an M group, wherein R 3 represents the groups defined above and M is an aromatic or heteroaromatic group, can be obtained by reaction of the organolithium compound XVI with a compound XX,
- a starting compound of formula VII can be obtained starting from a compound XXI through the process which is showed in scheme 3.
- a compound of formula XXII can be obtained starting from a compound XXI, commercial or easily obtainable through simple chemical processes, by chloromethylation with formaldehyde and hydrogen chloride in the presence of catalytic amounts of zinc chloride (II) or of aluminium trichloride or, alternatively, by reaction of
- a compound XXIII is obtained starting from a compound XXII by substitution of the chlorine atom by a cyano group with sodium or potassium cyanide in tetrahydrofuran, DMSO or ethanol at a temperature between 25°C and the solvent reflux (step 9).
- the obtained compound XXIII can be transformed into a compound VII by sequential alkylation with a suitable alkyl halide in the conditions described above for the preparation of Ila starting from IV (step 10).
- a compound XXV can be obtained by aminolysis with gaseous ammonia of a compound XXIV previously activated in the form of a mixed anhydride with a suitable chloroformate .
- the compound XXIV is reacted with ethyl chloroformate in the presence of an organic base such as triethylamine in a solvent such as tetrahydrofuran at room temperature for a time between 1 and 4 h, and the resulting anhydride is bubbled with gaseous ammonia in the presence of methanol or ethanol acting as solvents of the gas (step 11).
- Compound VII is obtained by dehydration of carboxamide XXV, for example, with phosphorous oxychloride in a solvent such as N, N-dimethylformamide at a temperature from 0° to 50°C and for a time ranging between 3 and 24 hours (step 12) .
- a solvent such as N, N-dimethylformamide
- a compound Xlb can be obtained starting from a compound XIa, by previously preparing the compound XIa acid chloride by treatment with, for example, phosphorous pentachloride , phosphorous trichloride or thionyl chloride in an inert solvent at a temperature from 25° to 80°C for a time between 1 and 24 hours and, after that, reacting the resulting sulfonic acid chloride with gaseous ammonia in a suitable solvent such as ethanol or methanol or mixtures thereof with a miscible solvent in which the product is soluble at room temperature for a time between 2 and 72 hours.
- a suitable solvent such as ethanol or methanol or mixtures thereof
- the compounds of general formula I object of the present invention, not only show a high inhibitory activity on cyclooxygenase-I , but also a marked selectivity for this isoenzyme vs.. cyclooxygenase-II. Surprisingly, these compounds also proved to hav_e antiinflammatory , antirheumatic and analgesic activities. Furthermore, in animal models with pre- existent ulcers and gastrointestinal disorders, they neither worsen the ulcers or erosions of the gastrointestinal mucosa, nor increase their incidence or severity, or delay the healing thereof.
- the enzymatic activity referred to in the present invention is illustrated by the capability of these compounds of inhibiting the production of thromboxanes (TxB 2 ) in human polymorphonuclear neutrophils (through cyclooxygenase-I inhibition) as well as of prostaglandins (PGE 2 ) in human monocytes stimulated with lipopolysaccharide (evaluation of the possible inhibition of cyclooxygenase-II).
- ICC Q values correspond to the ⁇ M inhibitory concentration necessary to reduce by 50% (compared with the control) the production of the concerned mediator.
- the ICC Q values inhibiting cyclooxygenase-I and cyclooxygenase-II corresponding to ( + )-S-ibuprofen are 0.15 ⁇ M and >1 ⁇ M, respectively, whereas for indomethacin I ⁇ Q are 0.19 ⁇ M and 0.0056 ⁇ M, respectively.
- the present invention also relates to the use of the compounds of general formula I in pharmaceutical compositions useful for the inhibition of cyclooxygenase or for the treatment of disorders related with this enzyme. More specifically, the present invention relates to the use of these compounds in pharmaceutical compositions useful for the selective inhibition of cyclooxygenase-I or for the treatment of disorders related with this enzyme.
- the compounds of general formula I of this invention are a new rational approach to the treatment of inflammation, rheumatism and pain, which can be also used in patients with pre- existent gastrointestinal disorders as these compounds have, in addition to their therapeutical activity, a reduced capability of causing additional undesired effects which would increase the severity of ulcers or delay the natural healing process thereof.
- the compounds of the invention due to the above cited pharmacological characteristics and toxicologic profile thereof, are useful as an alternative to the use of conventional NSAIDs, including those cases in which the latter can be contra-indicated, as it happens in patients with gastrointestinal ulcers or with relapses of gastric lesions, gastric bleeding and coagulation problems.
- the invention further relates .to the use of compounds I for the preparation of pharmaceutical compositions useful in the treatment of pain or fever associated with rheumatic fever, lumbar and cervical pains, viral infections, dysmenorrhea, headache or toothache, myositis, neuralgia, synovitis, arthritis including osteoarthritis and rheumatoid arthritis, ankylosing spondylitis, bursitis and burns, or in the treatment of diseases of inflammatory or allergic origin, such as allergic rhinitis, allergic conjunctivitis, rheumatoid arthritis, osteoarthritis, tendinitis, bursitis or psoriasis and, most specifically, to the therapeutical use in patients with gastrointestinal disorders pre-existent to.
- diseases of inflammatory or allergic origin such as allergic rhinitis, allergic conjunctivitis, rheumatoid arthritis, osteoarthritis, tendinitis, bursitis or psoriasis and,
- the combined organic phases are dried and the solvent is evaporated off under reduced pressure.
- the resulting residue is suspended in a mixture of glacial acetic acid (10 ml) and a 6M HC1 solution (65 ml) and stirred under reflux for 16 h.
- the mixture is cooled, added with water (25 ml), extracted with ethyl ether.
- the combined ether phases are washed with a 3M sodium hydroxide solution and dried and the solvent is evaporated off under reduced pressure.
- the residue is redissolved in dimethoxyethane (15 ml) and added, in succession, with water (10 ml) and with potassium hydroxide (1.0 g).
- the resulting crude from the previous step (1.84 g) is dissolved in a mixture of chloroform (10 ml), acetic anhydride (10 ml) and triethylamine (2 ml) and the resulting mixture is stirred under reflux for 5 h. After that the mixture is evaporated to dryness under reduced pressure and the resulting residue is partitioned between a mixture of a IM HCl solution and ethyl acetate. The aqueous phase is extracted with ethyl acetate, dried and the solvent is evaporated off under reduced pressure.
- the resulting residue is dissolved in a mixture of ethyl acetate (10 ml), ethanol (10 ml) and acetic acid (5 ml), then added with 10% palladium-on- charcoal (271 mg).
- the resulting mixture is hydrogenated under atmospheric pressure for 18 h.
- the catalyst is filtered off and the solvents are evaporated off under reduced pressure.
- the resulting residue is dissolved in tetrahydrofuran (20 ml) and added with a 50% sulfuric acid solution (10 ml). The mixture is refluxed for 6 h, then cooled to room temperature, diluted with water (30 ml) and extracted with chloroform.
- the resulting crude from the above step is suspended in a mixture of water (40 ml) and ethanol (100 ml) and added with sodium cyanide (1.79 g, 36.3 mmol), stirring under reflux for 4 h, then it is cooled to room temperature and added with ethyl ether (50 ml) and a sodium chloride saturated solution (50 ml). The two phases are separated and the aqueous phase is extracted with ethyl ether. The ether extracts are dried and the solvent is evaporated off, to obtain a crude which is purified by flash chromatography on silica gel column. Eluting with hexane: ethyl acetate, 3:2, 1.74 g of the title compound as a yellowish oil are obtained (27% yield).
- HMPA hexamethylphosphoramide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU83376/98A AU8337698A (en) | 1997-06-17 | 1998-06-17 | Cyclooxygenase-i selective inhibitors and the use thereof as analgesic, antiinflammatory and antiarthritic agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES9701315A ES2136018B1 (en) | 1997-06-17 | 1997-06-17 | SELECTIVE INHIBITOR COMPOUNDS OF CYCLOOXYGENASE-I AND ITS USE AS ANALGESICS, ANTI-INFLAMMATORIES AND ANTIARTHRITIC. |
ESP9701315 | 1997-06-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998057910A2 true WO1998057910A2 (en) | 1998-12-23 |
WO1998057910A3 WO1998057910A3 (en) | 1999-03-11 |
Family
ID=8299706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/003636 WO1998057910A2 (en) | 1997-06-17 | 1998-06-17 | Cyclooxygenase-i selective inhibitors and the use thereof as analgesic, antiinflammatory and antiarthritic agents |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU8337698A (en) |
ES (1) | ES2136018B1 (en) |
WO (1) | WO1998057910A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7183306B2 (en) | 2002-12-02 | 2007-02-27 | Astellas Pharma Inc. | Pyrazole derivatives |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2223855A1 (en) * | 1971-05-17 | 1972-12-07 | Bouchara, Emile, Dr., Paris | Derivatives of phenylacetic acid, process for their preparation and their use |
DE2253466A1 (en) * | 1972-10-31 | 1974-05-09 | Diamalt Ag | 4-Allyloxy-3-chlorophenylacetic acid prepn. - with anti-rheumatic activity, from 3-chloro-4-hydroxyphenylacetic acid and allyl halide |
DE2400531A1 (en) * | 1973-01-08 | 1974-07-25 | Manetti & Roberts Italo Brit | 2- (4-ISOBUTYLPHENYL) -PROPIOHYDROXAMIC ACID AND THEIR PRODUCTION |
DE2614306A1 (en) * | 1975-04-03 | 1976-10-21 | Prodotti Antibiotici Spa | METHOD FOR PRODUCING ISOBUTYLPHENYL COMPOUNDS |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4082707A (en) * | 1973-01-08 | 1978-04-04 | Societa Italo-Britannica L. Manetti-H. Roberts & Co. | 2-(4-isobutylphenyl)-propiohydroxamic acid and a procedure for its preparation |
JPS54163545A (en) * | 1978-06-10 | 1979-12-26 | Taisho Pharmaceutical Co Ltd | Organic carboxylic acid derivative |
JPS60155144A (en) * | 1984-01-24 | 1985-08-15 | Central Glass Co Ltd | Hexafluoroisobutylbenzene derivative and anti- inflammatory and analgesic agent containing same |
CS274344B1 (en) * | 1989-08-14 | 1991-04-11 | Protiva Miroslav | Method of 2-/4-(2-propylthio)phenyl/propionic acid's preparation |
GB2306191A (en) * | 1995-10-11 | 1997-04-30 | Delta 3 Ltd | A device for securing portable equipment |
-
1997
- 1997-06-17 ES ES9701315A patent/ES2136018B1/en not_active Expired - Fee Related
-
1998
- 1998-06-17 AU AU83376/98A patent/AU8337698A/en not_active Abandoned
- 1998-06-17 WO PCT/EP1998/003636 patent/WO1998057910A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2223855A1 (en) * | 1971-05-17 | 1972-12-07 | Bouchara, Emile, Dr., Paris | Derivatives of phenylacetic acid, process for their preparation and their use |
DE2253466A1 (en) * | 1972-10-31 | 1974-05-09 | Diamalt Ag | 4-Allyloxy-3-chlorophenylacetic acid prepn. - with anti-rheumatic activity, from 3-chloro-4-hydroxyphenylacetic acid and allyl halide |
DE2400531A1 (en) * | 1973-01-08 | 1974-07-25 | Manetti & Roberts Italo Brit | 2- (4-ISOBUTYLPHENYL) -PROPIOHYDROXAMIC ACID AND THEIR PRODUCTION |
DE2614306A1 (en) * | 1975-04-03 | 1976-10-21 | Prodotti Antibiotici Spa | METHOD FOR PRODUCING ISOBUTYLPHENYL COMPOUNDS |
Non-Patent Citations (7)
Title |
---|
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US STN, accession no. 104:45471, XP002089466 & S. HIGUCHI ET AL: NIPPON YAKURIGAKU ZASSHI, vol. 86, no. 6, 1985, pages 417-423, * |
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US STN, accession no. 104:50632, XP002089467 -& CHEMICAL ABSTRACTS, vol. 104, no. 7, 17 February 1986 Columbus, Ohio, US; abstract no. 50632u, XP002089464 & JP 60 155144 A (CENTRAL GLASS CO LTD ET AL) 15 August 1985 * |
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US STN, accession no. 119:180530, XP002089468 & CS 274 344 A (M. PROTIVA ET AL) 31 July 1992 * |
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US STN, accession no. 126:126651, XP002089469 & E.M. BONEBERG ET AL: J. CLIN. PHARMACOL., vol. 36, no. 12, Suppl, 1996, pages 16S-19S, * |
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US STN, accession no. 93:26117, XP002089465 -& CHEMICAL ABSTRACTS, vol. 93, no. 3, 21 July 1980 Columbus, Ohio, US; abstract no. 26117p, XP002089463 & JP 54 163545 A (TAISHO PHARMACEUTICAL CO LTD) 26 December 1979 * |
J.A. MITCHELL ET AL: PROC. NATL. ACAD. SCI. USA, vol. 90, 1994, pages 11693-11697, XP002089476 * |
T. FUJIYOSHI ET AL: CHEM. PHARM. BULL., vol. 37, no. 3, 1989, pages 775-777, XP002089462 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7183306B2 (en) | 2002-12-02 | 2007-02-27 | Astellas Pharma Inc. | Pyrazole derivatives |
Also Published As
Publication number | Publication date |
---|---|
WO1998057910A3 (en) | 1999-03-11 |
ES2136018B1 (en) | 2000-07-01 |
AU8337698A (en) | 1999-01-04 |
ES2136018A1 (en) | 1999-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5000683B2 (en) | Substituted phenylalkanoic acid derivatives and uses thereof | |
JP3704470B2 (en) | 5-alkyl-2-arylaminophenylacetic acid and derivatives | |
SU1169534A3 (en) | Method of obtaining derivatives of trisubstituted imidazoles of their salts with base | |
JPH09512798A (en) | Nitro compounds having anti-inflammatory, analgesic and antithrombotic activity and compositions thereof | |
AU2008222807A1 (en) | PPAR active compounds | |
EA012786B1 (en) | 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof | |
IL45585A (en) | 6,11-dihydrodibenz(b,e)oxepin-acetic acids and derivative | |
CA2400264A1 (en) | Cancer remedy comprising anthranilic acid derivative as active ingredient | |
US6867320B2 (en) | Substituted phenylalkanoic acid derivatives and use thereof | |
FI66369C (en) | FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA P-2-TENOYL) FENYLALKANSYROR OCH DERIVAT AV DESSA | |
US3468939A (en) | 4- and 5-aryl-1-naphthaleneacetic acid compounds | |
JPH0215048A (en) | Neopentyl ester derivative, and its production and use thereof as medicine | |
WO1998057910A2 (en) | Cyclooxygenase-i selective inhibitors and the use thereof as analgesic, antiinflammatory and antiarthritic agents | |
CS216207B2 (en) | Method of making the derivatives of the 1,4-diphenylpyrazole | |
NL7905774A (en) | PYRIDOXIN DERIVATIVES. | |
GB2181728A (en) | 4-(3-Thienyl)phenylalkanoic acids and derivatives and process for their preparation | |
US5508302A (en) | Phospholipase A2 inhibitors | |
KR790001825B1 (en) | Process for preparing stilbene derivatives | |
JPS6130669B2 (en) | ||
FI57592C (en) | ANALOGIFICATION OF THERAPEUTIC ACTIVATION OF THERAPEUTIC ACTIVE 5- (3-PHENOXYBENYL) -1H-TETRAZOLER | |
CA2154423A1 (en) | Phosphorylated derivatives of compositions having anti-inflammatory or analgesic activity and a method for the preparation thereof | |
JPS6033099B2 (en) | Novel naphthylpropionate derivatives | |
BE877953A (en) | PYRIDOXINE DERIVATIVES | |
JPS6245869B2 (en) | ||
JPS6041668B2 (en) | α-thio-α-(2-fluoro-4-biphenylyl)carboxylic acid derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP Ref document number: 1999503733 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: CA |